Nano skin treatment attracts German federal funding
York Pharma plc, the Hitchin based dermatology products specialist, has been awarded a one million euros grant from the German government for a programme to develop a novel treatment for acne.
Under the programme, York is conducting the development of sphingosine-1-phosphate (S1P), applied topically to the skin, as a novel therapeutic treatment.
S1P will be presented within a nano-particulate cream formulation. The novel nano-drug delivery system will be designed to enhance the access of the drug through the skin to the acne lesions.
Under York’s direction, several university facilities in Germany will collaborate with other industrial partners to optimise the nano-particle formulation and complete pre-clinical testing.
York will retain all commercial rights to the product.
S1P-related patents, know-how and global commercialisation rights were acquired by York last July from the inventors, headed by Professor Monika Schäfer-Korting of the Freie Universität Berlin.
Terry Sadler, York’s CEO, said: “This treatment will herald a totally new approach to the treatment of acne, a common condition, the incidence of which is continuing to increase.
“We are also fortunate to be working with highly skilled partners who will contribute their expertise to this exciting project.”